Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 12/02 05:57:46 am
418.85 DKK   +0.44%
12/01NOVO NORDISK A/S : - Company announcements, trading in own shares
AQ
12/01NOVO NORDISK A/S : ESG presentation ()
PU
12/01NOVO NORDISK : Gets a Buy rating from JP Morgan
MD
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
11/26/2020 11/27/2020 11/30/2020 12/01/2020 12/02/2020 Date
414.75(c) 419.25(c) 419.7(c) 417(c) 419.1 Last
1 152 365 1 858 758 5 514 825 2 285 151 574 355 Volume
+0.81% +1.08% +0.11% -0.64% +0.50% Change
More quotes
Financials
Sales 2020 127 B 20 689 M 20 689 M
Net income 2020 42 174 M 6 848 M 6 848 M
Net cash position 2020 8 472 M 1 376 M 1 376 M
P/E ratio 2020 23,0x
Yield 2020 2,16%
Sales 2021 135 B 21 930 M 21 930 M
Net income 2021 45 207 M 7 341 M 7 341 M
Net cash position 2021 12 773 M 2 074 M 2 074 M
P/E ratio 2021 21,1x
Yield 2021 2,33%
Capitalization 965 B 156 B 157 B
EV / Sales 2020 7,51x
EV / Sales 2021 7,05x
Nbr of Employees 44 326
Free-Float 75,1%
More Financials
Company
Novo Nordisk AS specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - products for treating diabetes and obesity (84.3%); - hemophilia treatment products (8.4%): mainly injections of protein; - growth hormones (6%): used for treatment of growth deficiencies in children; - hormone replacement products (1.3%): used for treatment of... 
Sector
Pharmaceuticals
Calendar
11/30 | 10:00amSpecial Situation
More about the company
Notations Surperformance© of Novo Nordisk A/S
Trading Rating : Investor Rating :
More Ratings
All news about NOVO NORDISK A/S
12/01NOVO NORDISK A/S : - Company announcements, trading in own shares
AQ
12/01NOVO NORDISK A/S : ESG presentation ()
PU
12/01NOVO NORDISK : Gets a Buy rating from JP Morgan
MD
11/30Weight-Loss Firm Noom Names First CFO
DJ
11/23NOVO NORDISK A/S : – Share repurchase programme
AQ
11/20India's Gland Pharma jumps 23% in market debut
RE
11/18NOVO NORDISK A/S : - Once-weekly semaglutide 2.0 mg demonstrates superior reduct..
AQ
11/18NOVO NORDISK A/S : Experts Urge Govt to Subsidise Cost of Diabetes Management, T..
AQ
11/17NOVO NORDISK A/S : Once-weekly semaglutide 2.0 mg demonstrates superior reductio..
AQ
11/16GILEAD SCIENCES : and Novo Nordisk Present New Data from Proof-of-Concept Trial ..
AQ
11/14NOVO NORDISK A/S : Diabetes - Novo Nordisk to Offer Free Insulin to Children in ..
AQ
11/12NOVO NORDISK A/S : set to acquire Emisphere for $1.8 billion
AQ
11/09NOVO NORDISK A/S : to acquire Emisphere Technologies and obtain ownership of the..
AQ
11/09NOVO NORDISK : UBS reiterates its Neutral rating
MD
11/09NOVO NORDISK : Downgraded to Sell by Morgan Stanley
MD
More news
News in other languages on NOVO NORDISK A/S
12/01NOVO NORDISK : JP Morgan optimiste sur le dossier
12/01JPMorgan belässt Novo Nordisk auf 'Overweight' - Ziel 470 Kronen
11/19Ypsomed confie à Eli Lilly la distribution future de l'Ypsopump aux Etats-Uni..
11/13Givaudan s'associe au danois Novozymes pour la recherche
11/12JPMorgan senkt Novo-Nordisk-Ziel auf 470 Kronen - 'Overweight'
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | MarketScreener
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Average target price 439,69 DKK
Last Close Price 417,00 DKK
Spread / Highest target 30,7%
Spread / Average Target 5,44%
Spread / Lowest Target -30,5%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S7.85%156 152
JOHNSON & JOHNSON1.08%388 168
ROCHE HOLDING AG-4.59%284 650
PFIZER, INC.6.17%219 056
MERCK & CO., INC.-10.34%206 324
NOVARTIS AG-11.46%205 415